Loading…
Employees: 115
Size HJ Science (6132.HK) is a Hong Kong Health Care company (Biotechnology) with a market value of $300M, the 887th largest of 891 Hong Kong companies the cockpit tracks. Shares closed at HK$31.96 on 6 Nov 2026.
Growth Revenue grew 621.4% over the last twelve months (peer median +7.0%); the operating margin is -966.6% (peer median -173.2%).
Valuation It trades at 65.6× enterprise value to sales against a peer median of 9.9× (3rd most expensive of 14).
| TTM | FY2025 | FY2024 | |
|---|---|---|---|
| Revenue | n/a | HK$14.1M | HK$1.95M |
| Revenue growth | — | +621% | — |
| EBITDA | n/a | -HK$133M | -HK$89.8M |
| Net income | n/a | -HK$147M | -HK$219M |
| Free cash flow | n/a | -HK$98.7M | -HK$85.3M |
| Capital expenditure | n/a | HK$1.64M | HK$1.77M |
| Total debt | n/a | HK$14.1M | HK$2.43M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | 6132.HK | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -16.7% | -11.3% | 8th lowest of 20 |
| Distance from 52-week high | -61.0% | -52.5% | 7th lowest of 20 |
| Revenue growth (TTM) | +621.4% | +7.0% | highest of 14 |
| Operating margin | -966.6% | -173.2% | 3rd lowest of 14 |
| EV / Sales | 65.6× | 9.9× | 3rd most expensive of 14 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| HJ Science 6132.HK | Hong Kong | $300M | n/a | +621% | -967% | 65.6× | n/a | n/a |
| Kyverna Therapeutics KYTX | United States | $302M | -48% | n/a | n/a | n/a | n/a | n/a |
| Circio CRNA.OL | Norway | $303M | -14% | n/a | n/a | n/a | n/a | n/a |
| Century Therapeutics IPSC | United States | $304M | -27% | -100% | n/a | n/a | n/a | n/a |
| Medy-Tox 086900.KS | South Korea | $310M | -39% | +7% | 7% | 2.0× | 6.0% | +11.9% |
| X4 Pharmaceuticals XFOR | United States | $315M | -28% | -52% | -555% | 11.6× | n/a | n/a |
| Galectin Therapeutics GALT | United States | $317M | +50% | n/a | n/a | n/a | n/a | n/a |
| Agenus AGEN | United States | $323M | +87% | +30% | 27% | 4.4× | n/a | n/a |
| TransThera Sciences (Nanjing) 2617.HK | Hong Kong | $323M | -83% | n/a | -751% | 36.4× | n/a | n/a |
| IMPACT Therapeutics 7630.HK | Hong Kong | $325M | n/a | +395% | -173% | 9.9× | n/a | n/a |
| Laekna 2105.HK | Hong Kong | $328M | -57% | n/a | -57% | 4.8× | n/a | n/a |
| AP Biosciences 6945.TWO | Taiwan | $330M | -32% | -100% | n/a | n/a | n/a | n/a |
| Benitec Biopharma BNTC | United States | $333M | -22% | n/a | n/a | n/a | n/a | n/a |
| Alector ALEC | United States | $340M | +9% | -83% | -857% | 14.4× | n/a | n/a |
| Cuorips 4894.T | Japan | $341M | -9% | -51% | -947% | 392.1× | n/a | n/a |
| Fennec Pharmaceuticals FENC | United States | $344M | +42% | +78% | -3% | 5.1× | n/a | n/a |
| ProKidney PROK | United States | $345M | -39% | +55% | -21,665% | 1,556.3× | n/a | n/a |
| Viva Biotech 1873.HK | Hong Kong | $354M | -14% | +7% | 10% | 1.2× | 5.6% | +19.1% |
| Medtide 3880.HK | Hong Kong | $358M | -9% | +14% | 36% | 2.7× | n/a | n/a |
| Allogene Therapeutics ALLO | United States | $359M | -54% | -100% | -3,886% | 22.8× | n/a | n/a |
| Aspen Neuroscience ASPE | United States | $362M | n/a | n/a | n/a | n/a | n/a | n/a |